Incidence of and Risk Factors for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant
JAMA Dermatology · 2025
DOI: 10.1001/jamadermatol.2024.5129 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2025. Verfasst von Kristy K Broman und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham, Birmingham. Hauptthemen laut MEDLINE: Skin Neoplasms, Bone Marrow Transplantation, Melanoma, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Cutaneous malignant neoplasms are the most common subsequent neoplasm after blood or marrow transplant (BMT), but a full assessment among survivors is lacking.
Objective
To identify risk factors for subsequent cutaneous malignant neoplasms using the BMT Survivor Study (BMTSS). Design, Setting, and Participants This retrospective cohort study included patients who underwent transplant from 1974 to 2014 at City of Hope, University of Minnesota, or University of Alabama at Birmingham and survived 2 years or longer, as well as a comparison cohort of siblings. Both groups completed the BMTSS survey. Data analysis took place from October 2022 to October 2024. Exposures Demographics, pre-BMT and BMT-related therapeutic exposures, chronic graft-vs-host disease (cGVHD), and posttransplant immunosuppression. Main Outcomes and Measures Incident cutaneous malignant neoplasms (basal cell carcinoma [BCC], squamous cell carcinoma [SCC], and melanoma) after BMT. Exposures were evaluated for association with subsequent neoplasms using proportional subdistribution hazards models (reported as subdistribution hazard ratio [SHR] and 95% CI).
Results
Among the 3880 BMT survivors (median [range] age at BMT, 44.0 [0-78.0] years; 2165 [55.8%] male; 190 [4.9%] Black, 468 [12.1%] Hispanic, 2897 [74.7%] non-Hispanic White, and 325 [8.4%] of other race [including Asian and Pacific Islander] and multiracial) who were followed up for a median (range) of 9.5 (2.0-46.0) years, 605 developed 778 distinct cutaneous neoplasms (BCC, 321; SCC, 231; melanoma, 78; and unknown type, 148). The 30-year cumulative incidence of any cutaneous malignant neoplasm was 27.4% (BCC, 18.0%; SCC, 9.8%; and melanoma, 3.7%). Seventy-year cumulative probabilities of BCC, SCC, and melanoma were considerably higher in BMT survivors than siblings (18.1% vs 8.2%, 14.7% vs 4.2%, and 4.2% vs 2.4%, respectively). Among BMT survivors, risk factors for subsequent cutaneous malignant neoplasms included age of 50 years and older at BMT (BCC: SHR, 1.76; 95% CI, 1.36-2.29; SCC: SHR, 3.37; 95% CI, 2.41-4.72), male sex (BCC: SHR, 1.39; 95% CI, 1.10-1.75; SCC: SHR, 1.85; 95% CI, 1.39-2.45), pre-BMT monoclonal antibody exposure (BCC: SHR, 1.71; 95% CI, 1.27-2.31), allogeneic BMT with cGVHD (BCC: SHR, 1.48; 95% CI, 1.06-2.08; SCC: SHR, 2.61; 95% CI, 1.68-4.04 [reference: autologous BMT]), post-BMT immunosuppression (BCC: SHR, 1.63; 95% CI, 1.24-2.14; SCC: SHR, 1.48; 95% CI, 1.09-2.02; melanoma: SHR, 1.90; 95% CI, 1.16-3.12), and transplant at City of Hope (BCC: SHR, 3.55; 95% CI, 2.58-4.89; SCC: SHR, 3.57; 95% CI, 2.34-5.47 [reference: University of Minnesota]) or University of Alabama at Birmingham (BCC: SHR, 2.35; 95% CI, 1.35-4.23; SCC: SHR, 2.63; 95% CI, 1.36-5.08 [reference: University of Minnesota]). Race and ethnicity other than non-Hispanic White were protective for BCC (Black: no cases; Hispanic: SHR, 0.27; 95% CI, 0.16-0.44; other race and multiracial: SHR, 0.26; 95% CI, 0.14-0.50 [reference: non-Hispanic White]) and SCC (Black: SHR, 0.17; 95% CI, 0.04-0.67; Hispanic: SHR, 0.28; 95% CI, 0.16-0.50; other race and multiracial: SHR, 0.13; 95% CI, 0.05-0.37 [reference: non-Hispanic White]). Total body irradiation was associated with BCC risk among those younger than 50 years at BMT (SHR, 1.92; 95% CI, 1.27-2.92). Conclusions and Relevance In this cohort study, the high risk of cutaneous malignant neoplasms and malignant-specific risk factors suggest a need for personalized patient counseling and posttransplant dermatologic surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University of Alabama at Birmingham, Birmingham.
- Birmingham VA Medical Center, US Department of Veterans Affairs, Birmingham, Alabama.
- Childhood Cancer Center, Skane University Hospital, Department of Clinical Sciences, Lund University, Lund, Sweden.
- City of Hope, Duarte, California.
- University of Minnesota, Minneapolis.
Förderung
- NCI NIH HHS
Zitieren
APA
Broman, K. K., Meng, Q., Holmqvist, A., Balas, N., Richman, J., Landier, W., Hageman, L., Ross, E., Bosworth, A., Te, H. S., Hollenquest, B., Wong, F. L., Bhatia, R., Forman, S. J., Armenian, S. H., Weisdorf, D. J., & Bhatia, S. (2025). Incidence of and Risk Factors for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.5129
Vancouver
Broman KK, Meng Q, Holmqvist A, Balas N, Richman J, Landier W, et al. Incidence of and Risk Factors for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant. JAMA Dermatology. 2025. doi:10.1001/jamadermatol.2024.5129
BibTeX
@article{Broman2025,
author = {Broman, Kristy K and Meng, Qingrui and Holmqvist, Anna and Balas, Nora and Richman, Joshua and Landier, Wendy and Hageman, Lindsey and Ross, Elizabeth and Bosworth, Alysia and Te, Hok Sreng and Hollenquest, Britany and Wong, F Lennie and Bhatia, Ravi and Forman, Stephen J and Armenian, Saro H and Weisdorf, Daniel J and Bhatia, Smita},
title = {Incidence of and Risk Factors for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant},
journal = {JAMA Dermatology},
year = {2025},
doi = {10.1001/jamadermatol.2024.5129}
}
EUVIMED